Our Experience
Our extensive experience enables us to craft innovative solutions to address our clients’ strategic and financial goals.
In depth expertise across life science transactions.
Select Transactions
M&A
Acquisition by Takara Bio USA
Acquisition by Takara Bio USA
OVERVIEW: Sale of single-cell spatial biology tools company.
AMOUNT: N/A
CLOSE DATE: January 2025
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of preclinical therapeutics company developing a platform technology with initial applications in metabolic disease.
AMOUNT: $1,000,000,000+
CLOSE DATE: June 2021
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of Disarm, a preclinical neuroscience company .
AMOUNT: $1,360,000,000+
CLOSE DATE: October 2020
Partnering
Licensing Agreement with AbbVie
Licensing Agreement with AbbVie
OVERVIEW: Option agreement for license to develop and commercialize reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis.
AMOUNT: $400,000,000+
CLOSE DATE: November 2023
Licensing Agreement with GSK
Licensing Agreement with GSK
OVERVIEW: Licensing agreement for Brexafemme, a US FDA approved anti-fungal treatment of vulvovaginal candidiasis.
AMOUNT: $593,000,000+
CLOSE DATE: May 2023
Global Partnership with AbbVie
Global Partnership with AbbVie
OVERVIEW: Global partnership between AbbVie and HotSpot, a discovery company developing small molecule therapies for cancer and autoimmune diseases, around its IRF5 program.
AMOUNT: $335,000,000+
CLOSE DATE: December 2022
Financing
Series B Preferred Stock
Series B Preferred Stock
OVERVIEW: Financing for oncology diagnostics leveraging AI for new, morphology-driven disease analysis.
AMOUNT: $20,700,000
CLOSE DATE: August 2024
Series D Preferred Stock
Series D Preferred Stock
OVERVIEW: Series C financing round for commercial-stage best-in-class epilepsy company.
AMOUNT: $114,000,000
CLOSE DATE: March 2021
Acquisition by Nektar
Acquisition by Nektar
OVERVIEW: Sale of respiratory device company.
AMOUNT: $32,000,000
CLOSE DATE: October 2005
Transaction History
Acquisition by Takara Bio USA
Acquisition by Takara Bio USA
OVERVIEW: Sale of single-cell spatial biology tools company.
AMOUNT: N/A
CLOSE DATE: January 2025
Sale of ALZET® line to Lafayette Instrument
Sale of ALZET® line to Lafayette Instrument
OVERVIEW: Sale of Durect’s ALZET® line of osmotic pumps to Lafayette Instrument Co..
AMOUNT: $17,500,000
CLOSE DATE: November 2024
Series B Preferred Stock
Series B Preferred Stock
OVERVIEW: Financing for oncology diagnostics leveraging AI for new, morphology-driven disease analysis.
AMOUNT: $20,700,000
CLOSE DATE: August 2024
Licensing Agreement with AbbVie
Licensing Agreement with AbbVie
OVERVIEW: Option agreement for license to develop and commercialize reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis.
AMOUNT: $400,000,000+
CLOSE DATE: November 2023
Equity Investment by Eli Lilly
Equity Investment by Eli Lilly
OVERVIEW: Series C financing round, with Eli Lilly participation, for clinical-stage metabolic company.
AMOUNT: N/A
CLOSE DATE: December 2023
Licensing Agreement with GSK
Licensing Agreement with GSK
OVERVIEW: Licensing agreement for Brexafemme, a US FDA approved anti-fungal treatment of vulvovaginal candidiasis.
AMOUNT: $593,000,000+
CLOSE DATE: May 2023
Global Partnership with AbbVie
Global Partnership with AbbVie
OVERVIEW: Global partnership between AbbVie and HotSpot, a discovery company developing small molecule therapies for cancer and autoimmune diseases, around its IRF5 program.
AMOUNT: $335,000,000+
CLOSE DATE: December 2022
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of preclinical therapeutics company developing a platform technology with initial applications in metabolic disease.
AMOUNT: $1,000,000,000+
CLOSE DATE: June 2021
Acquisition by Danaher/IDT
Acquisition by Danaher/IDT
OVERVIEW: Sale of NGS library preparation genomics kits company.
AMOUNT: N/A
CLOSE DATE: March 2021
Series D Preferred Stock
Series D Preferred Stock
OVERVIEW: Series C financing round for commercial-stage best-in-class epilepsy company.
AMOUNT: $114,000,000
CLOSE DATE: March 2021
Merger with Panacea
Merger with Panacea
Advisory services for merger with SPAC
OVERVIEW: Merger with Panacea, SPAC sponsored by EcoR1.
AMOUNT: $1,500,000,000
CLOSE DATE: February 2021
Global Partnership with Eisai
Global Partnership with Eisai
OVERVIEW: Partnership for digital cognitive assessment technologies.
AMOUNT: $45,000,000+
CLOSE DATE: October 2020
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of Disarm, a preclinical neuroscience company .
AMOUNT: $1,360,000,000+
CLOSE DATE: October 2020
Partnership with Sanofi
Partnership with Sanofi
OVERVIEW: Collaboration to develop and commercialization IRAK4 protein degrader therapies for immune-inflammatory diseases.
AMOUNT: $2,150,000,000+
CLOSE DATE: August 2020
Ex-US Partnership with Santen
Ex-US Partnership with Santen
OVERVIEW: Licensing agreement and equity investment for ex-US rights of jCell for the treatment of retinitis pigmentosa.
AMOUNT: $252,000,000+
CLOSE DATE: May 2020
Acquisition by Exact Sciences
Acquisition by Exact Sciences
OVERVIEW: Sale of Paradigm Diagnostics, a personalized cancer diagnostics company.
AMOUNT: N/A
CLOSE DATE: March 2020
Acquisition by Exact Sciences
Acquisition by Exact Sciences
OVERVIEW: Sale of Viomics, a company focused on biomarker discovery for cancer diagnostics.
AMOUNT: N/A
CLOSE DATE: March 2020
Acquisition by Altavant Services
Acquisition by Altavant Services
OVERVIEW: Sale of Onspira, a rare respiratory disease company.
AMOUNT: N/A
CLOSE DATE: December 2019
Strategic Investment and Partnership with IQVIA
Strategic Investment and Partnership with IQVIA
OVERVIEW: Series C financing round and collaboration agreement for genomic data company.
AMOUNT: N/A
CLOSE DATE: December 2019
Series A Preferred Stock
Series A Preferred Stock
OVERVIEW: Series A financing round, alongside a concurrent asset acquisition and operational company formation.
AMOUNT: $275,000,000
CLOSE DATE: October 2019
Merger with Oncternal
Merger with Oncternal
OVERVIEW: Reverse merger of public biopharma company focused on SARD/SARM program with private, clinical-stage oncology company.
AMOUNT: N/A
CLOSE DATE: June 2019
US Partnership for APADAZ with KVK
US Partnership for APADAZ with KVK
Transaction Amount: $56,400,000+
OVERVIEW: Collaboration and license agreement with KVK for US commercial rights to APADAZ for short-term management of acute pain.
AMOUNT: $56,400,000+
CLOSE DATE: October 2018
Acquisition by Ligand
Acquisition by Ligand
OVERVIEW: Sale of Crystal Bioscience, a leader in avian genetics and the generation of fully-human therapeutic antibodies, to Ligand.
AMOUNT: $36,000,000
CLOSE DATE: October 2017
Spinout from Mt. Sinai Health Systems
Spinout from Mt. Sinai Health Systems
OVERVIEW: Spin out of a clinical genetics diagnostic business from a non-profit academic institution, Mt. Sinai Health System, to a for-profit standalone next-generation genetic information company
AMOUNT: N/A
CLOSE DATE: June 2017
Partnership with AstraZeneca
Partnership with AstraZeneca
OVERVIEW: Strategic collaboration to develop up to five Anticalin-based inhaled drugs for respiratory diseases
AMOUNT: $2,100,000,000
CLOSE DATE: June 2017
Merger with Daré
Merger with Daré
OVERVIEW: Reverse merger of a US-listed public, biopharmaceutical company with a private, clinical-stage Women’s Health company
AMOUNT: N/A
CLOSE DATE: July 2017
Sale of CTP-656 to Vertex
Sale of CTP-656 to Vertex
OVERVIEW: Fairness opinion for sale of clinical stage drug candidate to large pharma
AMOUNT: $250,000,000
CLOSE DATE: March 2017
Acquisition of US/CAN Rights to Zoladex from AstraZeneca
Acquisition of US/CAN Rights to Zoladex from AstraZeneca
OVERVIEW: Acquisition of the commercial rights in the US and Canada to Zoladex, a marketed cancer therapeutic, from AstraZeneca
AMOUNT: $320,000,000
CLOSE DATE: October 2017
Merger with Capnia
Merger with Capnia
OVERVIEW: Reverse merger into a publicly held company to create rare disease therapeutics company
AMOUNT: N/A
CLOSE DATE: December 2016
Acquisition of Performance Optics
Acquisition of Performance Optics
OVERVIEW: Purchase of Performance Optics, a privately-held ophthalmic lens manufacturer
AMOUNT: $476,000,000
CLOSE DATE: August 2017
N. & S. America and Indian Partnership with Metchuen
N. & S. America and Indian Partnership with Metchuen
OVERVIEW: One of four regional licensing agreements completed with Vivus
AMOUNT: $70,000,000
CLOSE DATE: October 2016
Preferred Stock
Preferred Stock
OVERVIEW: Series A and Series B preferred stock financing to continue development of dalcetrapib for treatment of cardiovascular disease
AMOUNT: $150,000,000
CLOSE DATE: April 2016
Acquisition by Becton Dickinson
Acquisition by Becton Dickinson
OVERVIEW: Sale of a privately held company with advanced tools for massively parallel single cell genetic analysis
AMOUNT: N/A
CLOSE DATE: August 2015
Acquisition by Midatech
Acquisition by Midatech
OVERVIEW: Sale of publicly traded specialty pharma company
AMOUNT: N/A
CLOSE DATE: June 2015
Acquisition by Boston Scientific
Acquisition by Boston Scientific
OVERVIEW: Sale of a privately held, venture-backed GI device company with strong early commercial traction
AMOUNT: $75,000,000+
CLOSE DATE: April 2015
Strategic Investment by Hanmi
Strategic Investment by Hanmi
OVERVIEW: Strategic investment and out-licensing of lead product in Korea and China
AMOUNT: $20,000,000+
CLOSE DATE: January 2015
Acquisition of SPRIX from Luitpold
Acquisition of SPRIX from Luitpold
OVERVIEW: Acquisition of SPRIX, a marketed pain management therapeutic, from Luitpold Pharmaceuticals
AMOUNT: N/A
CLOSE DATE: January 2015
Partnership with Curetech
Partnership with Curetech
OVERVIEW: In-licensing of clinical stage anti-PD-1 immunotherapy, Pidilizumab
AMOUNT: $335,000,000
CLOSE DATE: October 2014
Acquisition by Nicox S.A.
Acquisition by Nicox S.A.
OVERVIEW: Sale of a privately held, venture-backed ophthalmology therapeutics company
AMOUNT: $120,000,000
CLOSE DATE: July 2014
Series B Preferred Stock & Debt
Series B Preferred Stock & Debt
OVERVIEW: Growth capital for private, commercial-stage hip and knee implant company
AMOUNT: $43,400,000
CLOSE DATE: April 2014
Acquisition of SPL
Acquisition of SPL
OVERVIEW: Acquisition of privately held manufacturer and supplier of heparin
AMOUNT: $337,500,000+
CLOSE DATE: January 2014
Acquisition by Becton Dickinson
Acquisition by Becton Dickinson
OVERVIEW: Sale of a privately held diagnostic instrument company with a commercialize product in the point-of-care market
AMOUNT: $40,000,000
CLOSE DATE: January 2014